A.I. BURNASYAN FMBC CLINICAL BULLETIN

ISSN 2782-6430 (print)

State Research Center −Burnasyan Federal Medical Biophysical
Center of Federal Medical Biological Agency

The journal is published in Russian.
Format – A4.
The periodicity of the journal is 4 times a year.

Issue №4, 2026

A.I. Burnasyan  FMBC clinical bulletin. 2026 № 4

Interleukin-2: Biological Role and Clinical Significance

A.A. Ilyin, T.M. Bogdanova, P.M. Baranova, A.A. Bogomolov, A.S. Arefkina

Saratov State Medical University named after Razumovsky, Russiа

Contact person: Alexey A. Ilyin: e-mail: iljin2006@yandex.ru

 

Abstract
This article focuses on Interleukin 2, one of the major cytokines. It presents current data on the cytokine’s structure, mechanisms of action, and its role in the development of somatic, oncological, autoimmune, infectious diseases, and transplantation. Interleukin 2 preparations used in the treatment of diseases are presented.

Keywords: interleukin-2; IL-2; cytokines; myocardial infarction; chronic heart failure; myocardial remodeling; immune regulation; immunomodulation, sclerosis, sepsis

For citation: Ilyin AA, Bogdanova TM, Baranova PM, Bogomolov AA, Arefkina AS. Interleukin-2: biological role and clinical significance. A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin. 2026.4:76-81. (In Russian) DOI: 10.33266/2782-6430-2026-4-76-81

 

REFERENCES

  1. Radi H., Ferdosi-Shahandashti E., Ali Kardar G., et al. An Updated Review of Interleukin-2 Therapy in Cancer and Autoimmune Diseases. J. Interferon Cytokine Res. 2024;44;4:143–157. Doi: 10.1089/jir.2023.0178.
  2. Lim T.Y., Perpiñán E., Londoño M.C., et al. Low Dose Interleukin-2 Selectively Expands Circulating Regulatory T Cells but Fails to Promote Liver Allograft Tolerance in Humans. J. Hepatol. 2023;78;1:153–164. Doi: 10.1016/j.jhep.2022.09.023.
  3. Rafaqat S., Manzoor J., Akhter R., et al. Role of IL-2/IL-2 Receptor in Pathogenesis of Autoimmune Diseases. World J. Immunol. 2023;11;3:28–45. Doi: 10.5501/wji.v11.i3.28.
  4. Klyscz P., Otto C., Ruprecht K., et al. Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in Neuromyelitis Optica Spectrum Disorders. Annals of Clinical and Translational Neurology. 2025;12:2214–2225. Doi: 10.1002/ana.12345.
  5. Oportus J., Hojman L., Gonzalez V., Karsulovic C., et al. Soluble IL-2R as a Marker of T Cell Activation in Immune-Mediated Diseases. Lymphatics. 2025;3;1:1-18. Doi: 10.3390/immuno3010001.
  6. Raeber M.E., Schmid M., Keller A., et al. A Systematic Review of Interleukin-2-Based Immunotherapies in Clinical Trials for Cancer and Autoimmune Diseases. EBioMedicine. 2023;90:104539. Doi: 10.1016/j.ebiom.2023.104539.
  7. Shouse Acacia N., LaPorte Kathryn M., et al. Interleukin-2 Signaling in the Regulation of T Cell Biology. Immunity. 2024;57;3:414–428. Doi: 10.1016/j.immuni.2024.02.001.
  8. Harris F., Berdugo Y.A., Timothy T., et al. IL-2-Based Approaches to Treg Enhancement. Clin. Exp. Immunol. 2023;211;2:149–163. Doi: 10.1093/cei/uxac099.
  9. Im S.J., Lee Kyungmin, Ha Sang-Jun, et al. Harnessing IL-2 for Immunotherapy Against Cancer and Autoimmune Diseases. Exp. Mol. Med. 2024;56;9:1900-1908. Doi: 10.1038/s12276-024-01301-3.
  10. Peerlings D., Mimpen M., Damoiseaux J., et al. IL-2 Receptor Pathway: Key to Understanding Multiple Sclerosis. Journal of Translational Autoimmunity. 2022;21;3:103025. Doi: 10.1016/j.autrev.2021.103025.
  11. Buchbinder E., Little S.C., Pinato D.J., et al. Role of High-Dose Interleukin-2 for Melanoma in the Age of Immunotherapy. J. Immunother. Cancer. 2025;13;5:e011119. Doi: 10.1136/jitc-2025-011119.
  12. Rokade S., Patel P., Singh A., et al. IL-2 Based Cancer Immunotherapies: an Evolving Paradigm. Front. Immunol. 2024;15:1442673. Doi: 10.3389/fimmu.2024.1442673.
  13. Ko B., Kim Ji-Eun, -Hwan Lee Seung, et al. Rethinking Oncologic Treatment Strategies with Interleukin-2. Cells. 2023;12;9:1316. Doi: 10.3390/cells12091316.
  14. Dong S., Zhao M., Zhu J., et al. Natural Killer Cells: a Future Star for Immunotherapy of Head and Neck Squamous Cell Carcinoma. Front. Immunol. 2024;15:1442673.
  15. Tanigawa K., Redmond W.L. Current Landscape and Future Prospects of Interleukin-2-Based Immunotherapies. OncoImmunology. 2025;14;1:2452654. Doi: 10.1080/2162402X.2025.2452654.
  16. Rokade S., Damani A.M., Oft M., et al. IL-2 Based Cancer Immunotherapies: an Evolving Paradigm. Front. Immunol. 2024;15:1442673. Doi: 10.3389/fimmu.2024.1442673.
  17. Bulgarelli J., Piccinini C., Petracci E. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results. Front. Immunol. 2021;12:778459. Doi: 10.3389/fimmu.2021.778459.
  18. Zhai G.H., Zhang W., Xiang Z. Diagnostic Value of sIL-2R, TNF-α and PCT for Sepsis. Front. Immunol. 2021;12:741268. Doi: 10.3389/fimmu.2021.741268.
  19. Yan Huanhuan, Yan Huer, Liu Lu. Low-Dose Interleukin-2 Treatment Increases the Proportion of Regulatory T Cells in Patients with Rheumatic Diseases: a Meta-Analysis. Autoimmun. Rev. 2023;22;3:103267. Doi: 10.1016/j.autrev.2023.103267.
  20. Schumacher L., Müller A., Koch A., et al. Increased Serum Soluble Interleukin-2 Receptor in Systemic Sclerosis. Clinical and Experimental Rheumatology. 2025;43;8:1446–1454.
  21. Heymach J.V., Previs R., Sullivan R., et al. Phase 1a/1b Study of STK-012. Cancer Research. 2025;85;12(Suppl):CT244.
  22. He J., Chen J., Miao M., et al. Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome. JAMA Netw. Open. 2022;5;11:e2241451. Doi: 10.1001/jamanetworkopen.2022.41451.
  23. Su Q., Wang X., Li Y., et al. Efficacy, Safety and the Lymphocyte Subset Changes of Low-Dose IL-2 in Patients with Autoimmune Rheumatic Diseases. Rheumatol. Ther. 2024;11;1:79-96. Doi: 10.1007/s40744-023-00620-7.
  24. Lorenzon R., Rosenzwajg M., Cacou P., et al. The Universal Effects of Low-Dose Interleukin-2 Across 13 Autoimmune Diseases. J. Autoimmun. 2024;144:103172. Doi: 10.1016/j.jaut.2024.103172.
  25. Zhou P., Li Y., Wang X. Emerging Mechanisms and Applications of Low-Dose IL-2 Therapy in Autoimmunity. Cytokine Growth Factor Rev. 2022;67:80–88. Doi: 10.1016/j.cytogfr.2022.06.003.
  26. To J., Smith M., Patel A. Pharmacokinetic and Pharmacodynamic Profile of a First-in-Human Study with MDNA11, an Engineered Long-Acting Beta-Only IL-2 Agonist. Journal for ImmunoTherapy of Cancer. 2024;12;2:A776. Doi: 10.1186/s40495-024-00987-x.
  27. Raeber M.E., Heimberg L.C., Doering J.S., et al. Interleukin-2 Immunotherapy Reveals Human Regulatory T-Cell Subsets with Distinct Functional and Transcriptomic Profiles. Immunity. 2024;57;8:1895–1912. Doi: 10.1016/j.immuni.2024.07.003.
  28. Murer P., Brannetti B., Rondeau J.-M., et al. Discovery and Development of ANV419, an IL-2/anti-IL-2 Antibody Fusion Protein. Nature Reviews Drug Discovery. 2023 (in press). Doi: 10.1038/s41573-023-00687-w.
  29. Farooq A., Khan S., Rehman M., et al. A Comprehensive Review of Low-Dose Interleukin-2 (IL-2) Therapy in Autoimmune Diseases. J. Clin. Med. 2024;13;19:5932. Doi: 10.3390/jcm13195932.
  30. Yuan Y., Li X., Wang J., et al. Therapeutic Potential of Interleukin-2 in Autoimmune Diseases. Front. Immunol. 2022;13:890356. Doi: 10.3389/fimmu.2022.890356.
  31. Chanpura A., Patel S., Lee M., et al. Diagnostic Value of Soluble Interleukin-2 Receptor in Neurosarcoidosis. J. Cent. Nerv. Syst. Dis. 2024;16:11795735241274186.
  32. Wang J., Zhang Y., Chen L., et al. Low-Dose IL-2 Improved Clinical Symptoms by Restoring Treg Cells. Front. Immunol. 2022;13:9744779. Doi: 10.3389/fimmu.2022.9744779.
  33. Robert J., Evans M., Singh K., et al. Expression of an Interleukin-2 Partial Agonist Enhances Regulatory T-Cell Persistence. Nat. Commun. 2025;16:60082. Doi: 10.1038/s41467-025-60082-z.
  34. Vasselli J.R., Patel S., Kim J., et al. Trial in Progress: AB248, a CD8+ Selective IL-2 Mutein. Journal for ImmunoTherapy of Cancer. 2025;13;1:A849. Doi: 10.1136/jitc-2025-004849.
  35. Lopes J.E., Fisher J.L., Flick H.L., Wang C., Sun L., Ernstoff M.S., et al. ALKS 4230: a Novel Engineered IL-2 Fusion Protein with an Improved Cellular Selectivity Profile for Cancer Immunotherapy. Journal for ImmunoTherapy of Cancer. 2020;8:e000673. Doi: 10.1136/jitc-2020-000673.
  36. Liu Y., Liu F., Wang C., Yan Y., Yuan X., Chu Q. Tumor-Agnostic Therapy: a Potential Therapeutic Approach for SMARCA4-Deficient Malignancies. Transl Lung Cancer Res. 2025;14;11:567–589. Doi: 10.21037/tlcr-2025-921.
  37. Stockmann A.P., Vincent S., Herschelman L., Huang C.S., Ma J., Fallon D., Kirby P., Gutierrez E., Talbot D., Hicks S.W., Wagtmann N., Cheung A.F. DF6215, an α-Optimized IL-2-Fc Fusion, Expands Immune Effectors and Drives Robust Preclinical Anti-Tumor Activity. Cell Rep Med. 2026;7;1:102518. Doi: 10.1016/j.xcrm.2025.102518.
  38. Fu Y., Tang R., Zhao X. Engineering Cytokines for Cancer Immunotherapy: a Systematic Review. Front Immunol. 2023;14:1218082. Doi: 10.3389/fimmu.2023.1218082.
  39. Amini L., Kaeda J., Weber O., Reinke P. Low-Dose Interleukin-2 Therapy: Fine-tuning Treg in Solid Organ Transplantation? Transplantation. 2024;108;7:1492–1508. Doi: 10.1097/TP.0000000000004866..
  40. Graßhoff H., Comdühr S., Monne L.R., Müller A., Lamprecht P., Riemekasten G., Humrich J.Y. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases. Front Immunol. 2021;12:648408. Doi: 10.3389/fimmu.2021.648408.

Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship. 
Contribution. Article was prepared with equal participation of the authors.
Article received: 06.02.2026. Accepted for publication: 26.10.2026

Scroll to Top